Fluocinolone Acetonide 0.18 mg · intravitreal implant
Injections & Implants, Steroid
Approved uses
Chronic non-infectious uveitis affecting the posterior segment
One 0.18 mg implant intravitreally, releasing over about 36 months
Chosen when uveitis is chronic enough that repeated injections or systemic steroid are the alternative
Contraindications
- Active or suspected ocular or periocular infection, including most viral diseases of the cornea and conjunctiva, such as active epithelial herpes simplex keratitis, vaccinia and varicella, and mycobacterial and fungal infections
- Known hypersensitivity to any components of this product
0.18 mg fluocinolone acetonide intravitreal implant in a sterile single-dose preloaded applicator with a 25-gauge needle.
Corticosteroids inhibit inflammatory responses to a variety of inciting agents including multiple inflammatory cytokines. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. Corticosteroids are thought to act by inhibition of phospholipase A 2 via induction of inhibitory proteins collectively called lipocortins. It is postulated that these proteins control biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting release of the common precursor, arachidonic acid.
Warnings & Precautions
- Endophthalmitis and retinal detachment: intravitreal injection has been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure and choroidal or retinal detachment. Hypotony has been seen within 24 hours of injection and resolved within 2 weeks; monitor after injection.
- Cataract, glaucoma and ocular infection: corticosteroids may cause posterior subcapsular cataract, raised intraocular pressure and glaucoma, and may enhance secondary ocular infection by bacteria, fungi or viruses. They are not recommended in patients with a history of ocular herpes simplex, because the virus may reactivate.
- Implant migration: the implant may migrate into the anterior chamber if the posterior capsule is not intact.
- Ocular infection: do not use in active or suspected ocular or periocular infection.
Common Side Effects
In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure. Through 12 months, cataract occurred in 56% of YUTIQ study eyes that were phakic at baseline, versus 23% with sham. IOP elevation of 10 mmHg or more from baseline occurred in 22% of YUTIQ eyes versus 12% with sham, and any IOP-lowering medication was used in 43% of YUTIQ eyes versus 41% of sham eyes. Other ocular adverse reactions included visual acuity reduced (15%), macular edema (11%), uveitis (10%), conjunctival hemorrhage (8%), eye pain (8%) and hypotony of eye (7%).
Pregnancy: Adequate and well-controlled studies have not been conducted in pregnant women; animal reproduction studies have not been conducted with the implant. Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Give YUTIQ to a pregnant woman only if the potential benefit justifies the potential risk to the fetus.
Lactation: Systemically administered corticosteroids are present in human milk and can suppress growth and interfere with endogenous corticosteroid production. It is not known whether intravitreal treatment with YUTIQ could result in sufficient systemic absorption to produce detectable quantities of fluocinolone acetonide in human milk. Consider the benefits of breastfeeding along with the mother's clinical need for YUTIQ and any potential adverse effects on the breastfed child.
Safety and effectiveness of YUTIQ in pediatric patients have not been established.